… The aim of this study was to investigate the efficacy and safety of anlotinib for patients with
advanced non-small cell lung cancer (NSCLC) who progressed after standard regimens in …

… Our research results demonstrate that anlotinib is an effective regimen for third-line or
more-line treatment of advanced lung cancer and tolerance to anlotinib therapy is acceptable. In …

Purpose Anlotinib is a newly developed oral multitarget tyrosine kinase inhibitor. We
retrospectively evaluated the toxicity and clinical efficacy of chemotherapy combined with anlotinib …

… of anlotinib were summarized with a focus on safety evaluation and adverse event management.
… was indicated to be manageable and the recommended regimen was well tolerated. …

… A total of 36 patients with SCLC who were treated with at least one previous systemic
chemotherapy regimen participated in this study retrospectively. All the patients were administered …

… Some of the advanced SCLC patients who were still taking the anlotinib and PD-1/PD-L1
inhibitors combination regimen had long-lasting benefits, with their PFS exceeding 20 months …

… Anlotinib is a novel multi-target tyrosine kinase inhibitor that is … the safety, pharmacokinetics,
and antitumor activity of anlotinib … The recommended treatment regimen for the following …

… anlotinib in SCLC at the frontline. Therefore, this study aimed to analyze real-world data on
anlotinib to evaluate whether anlotinib … with an anlotinib-containing regimen was 7.9 months. …

… years, etoposide plus platinum chemotherapy regimens were widely accepted as the standard
first-line therapy for SCLC. Although a high rate of response of the regimen was achieved, …

… Doxorubicin is currently the standard first-line regimen for most patients with advanced STS.
Outcomes for those patients are poor, with an objective response rate (ORR) of about 14%, …